Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

An improvement in progression-free survival was shown with trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer in the progression-free survival interim analysis of the DESTINY-Breast03 trial. The aim of DESTINY-Breast03 was to compare the effic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet (British edition) 2023-01, Vol.401 (10371), p.105-117
Hauptverfasser:	Hurvitz, Sara A, Hegg, Roberto, Chung, Wei-Pang, Im, Seock-Ah, Jacot, William, Ganju, Vinod, Chiu, Joanne Wing Yan, Xu, Binghe, Hamilton, Erika, Madhusudan, Srinivasan, Iwata, Hiroji, Altintas, Sevilay, Henning, Jan-Willem, Curigliano, Giuseppe, Perez-Garcia, José Manuel, Kim, Sung-Bae, Petry, Vanessa, Huang, Chiun-Sheng, Li, Wei, Frenel, Jean-Sebastien, Antolin, Silvia, Yeo, Winnie, Bianchini, Giampaolo, Loi, Sherene, Tsurutani, Junji, Egorov, Anton, Liu, Yali, Cathcart, Jillian, Ashfaque, Shahid, Cortés, Javier
Format:	Artikel
Sprache:	eng
Schlagworte:	Ado-Trastuzumab Emtansine Ado-Trastuzumab Emtansine - therapeutic use Antibodies Antineoplastic Combined Chemotherapy Protocols Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast cancer Breast Neoplasms Breast Neoplasms - pathology Cancer Cancer therapies Clinical trials Effectiveness ErbB-2 protein FDA approval Female Humans Immunotherapy Interactive systems Intravenous administration Intravenous infusion Investigations Life Sciences Lung diseases Metastases Metastasis Monoclonal antibodies Pneumonitis Randomization Receptor, ErbB-2 Response rates Safety Safety analysis Safety management Solid tumors Survival Targeted cancer therapy Trastuzumab Trastuzumab - adverse effects Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!